Document is current

Article History

Received: 25 March 2024

Revised: 13 June 2024

Accepted: 15 June 2024

First Online: 8 July 2024

Declarations

:

: Dr. Abboud is a consultant and speaker for Biogen, Genentech, BMS, Horizon, and Alexion. He has served as a consultant and/or advisory board member for Cycle pharma and Alpine Pharma. He received honoraria from <i>Neurology Live</i>. He receives research support from Genentech, BMS, Novartis, Sanofi, UCB, and the Guthy-Jackson Charitable Foundation. He serves as an Assistant Editor for the <i>Neurology</i> Journal. He receives royalties from UpToDate. Dr Levy received personal compensation from Alexion, Horizon, Genentech, UCB Pharma, Quest Diagnostics, and Mitsubishi Tanabe Pharma Corporation, and research grants from Alexion, Horizon, and Genentech. He serves as a co-editor of the <i>Multiple Sclerosis and related Disorders</i> Journal and the editor-in-chief of <i>Neuroimmunology Reports</i>. All other authors report no disclosures. The authors declare no conflict of interest related to this research. Full financial disclosures for the past year are included at the end of the manuscript.

: This study was approved by the institutional review board of University Hospitals Cleveland Medical Center. A written informed consent was obtained from patients in whom identifiable videos were obtained. Source data can be made available for any qualified investigator.